These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 29450644)
1. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft. Chen P; Wen X; Wang B; Hou D; Zou H; Yuan Q; Yang H; Xie J; Huang H Ann Hematol; 2018 May; 97(5):865-875. PubMed ID: 29450644 [TBL] [Abstract][Full Text] [Related]
2. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts. Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768 [TBL] [Abstract][Full Text] [Related]
3. Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Meng H; Yang C; Jin J; Zhou Y; Qian W Leuk Lymphoma; 2008 Oct; 49(10):1954-62. PubMed ID: 18949618 [TBL] [Abstract][Full Text] [Related]
4. The synergistic killing of AML cells co-cultured with HS-5 bone marrow stromal cells by As2O3 and the PI3K/Akt signaling pathway inhibitor LY294002. Chen P; Wu J; Yuan Q; Jiang X; Huang H Pharmazie; 2015 May; 70(5):322-7. PubMed ID: 26062301 [TBL] [Abstract][Full Text] [Related]
5. Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway. Nan Y; Guo L; Song Y; Wang L; Yu K; Huang Q; Zhong Y J Cancer Res Clin Oncol; 2017 Aug; 143(8):1477-1487. PubMed ID: 28401302 [TBL] [Abstract][Full Text] [Related]
6. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells]. Liu Y; Chen X; Luo Z Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Xie X; Tang B; Zhou J; Gao Q; Zhang P Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572 [TBL] [Abstract][Full Text] [Related]
8. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines. Badinloo M; Esmaeili-Mahani S Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575 [TBL] [Abstract][Full Text] [Related]
9. [Homoharringtonine combined arsenic trioxide induced apoptosis in human multiple myeloma cell line RPMI 8226: an experimental research]. Zhou XJ; Zhou YH; Chen XH; Qian WB Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):834-9. PubMed ID: 23980369 [TBL] [Abstract][Full Text] [Related]
10. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. Nguyen DM; Chen GA; Reddy R; Tsai W; Schrump WD; Cole G; Schrump DS J Thorac Cardiovasc Surg; 2004 Feb; 127(2):365-75. PubMed ID: 14762343 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321 [TBL] [Abstract][Full Text] [Related]
12. Homoharringtonine Exerts an Antimyeloma Effect by Promoting Excess Parkin-Dependent Mitophagy. Zhang Y; Huang N; Xu J; Zheng W; Cui X Drug Des Devel Ther; 2020; 14():4749-4763. PubMed ID: 33177810 [TBL] [Abstract][Full Text] [Related]
13. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation. Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819 [TBL] [Abstract][Full Text] [Related]
14. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Tabe Y; Jin L; Tsutsumi-Ishii Y; Xu Y; McQueen T; Priebe W; Mills GB; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M Cancer Res; 2007 Jan; 67(2):684-94. PubMed ID: 17234779 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387 [TBL] [Abstract][Full Text] [Related]
16. Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling pathways. Shi X; Zhu M; Gong Z; Yang T; Yu R; Wang J; Zhang Y Food Chem Toxicol; 2020 Feb; 136():110960. PubMed ID: 31726078 [TBL] [Abstract][Full Text] [Related]
17. Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin. Kuroda J; Kamitsuji Y; Kimura S; Ashihara E; Kawata E; Nakagawa Y; Takeuichi M; Murotani Y; Yokota A; Tanaka R; Andreeff M; Taniwaki M; Maekawa T Int J Hematol; 2008 Jun; 87(5):507-515. PubMed ID: 18415656 [TBL] [Abstract][Full Text] [Related]
18. Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K/Akt-p27(Kip1) axis. Chen P; Huang H; Wu J; Lu R; Wu Y; Jiang X; Yuan Q; Chen Y Mol Carcinog; 2015 Dec; 54(12):1678-85. PubMed ID: 25408361 [TBL] [Abstract][Full Text] [Related]
19. [Effects of PD98059 and LY294002 on subcutaneous xenograft of human endometrial carcinoma in nude mice]. Guo RX; Zhang RF; Wang XY; Shi HR; Qiao YH Zhonghua Fu Chan Ke Za Zhi; 2011 Jun; 46(6):446-52. PubMed ID: 21781587 [TBL] [Abstract][Full Text] [Related]
20. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]